Benzinga
Benzinga
Benzinga
miércoles, septiembre 30

Amgen Inc

AMGNNASDAQ
Trade with Public
Trade with Public
$424.58
0.940.22%
Últ. Act.: Sep 30, 11:30 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadDividendosCompararInforme de acciones

Amgen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amgen (AMGN).

Price Target Range — 8 Quarters

Analyst Consensus — 22 Analysts

8Buy
12Hold
2Sell
Consensus RatingNeutral# Analysts22Avg. Consensus PT$383Upside to Avg. PT-9.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →
DateFirmAnalystActionRating ChangePrice Target
Sep 29, 2026ScotiabankLouise ChenPT RaiseSector Outperform$450→$500
Sep 10, 2026HSBCMorten HerholdtDowngradeBuy→Hold$445→$425
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $500

Scotiabank analyst Louise Chen maintains Amgen (NASDAQ:AMGN) with a Sector Outperform and raises the price target from $450 to $500.
Benzinga Newsdesk

Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data

Amgen's Phase 3 study shows dazodalibep significantly improves systemic disease activity in adults with Sjögren's disease.
Vandana Singh

PRO
HSBC Downgrades Amgen to Hold, Lowers Price Target to $425

HSBC analyst Morten Herholdt downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and lowers the price target from $445 to $425.
Benzinga Newsdesk

This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.
Avi Kapoor

PRO
BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450

BMO Capital analyst Evan David Seigerman downgrades Amgen (NASDAQ:AMGN) from Outperform to Market Perform and maintains the price target from $450 to $450.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Neutral on Amgen, Maintains $400 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Amgen (NASDAQ:AMGN) with a Neutral and maintains $400 price target.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved